Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Short-term Investments (2017 - 2025)

Historic Short-term Investments for Anaptysbio (ANAB) over the last 11 years, with Q3 2025 value amounting to $139.1 million.

  • Anaptysbio's Short-term Investments fell 4167.63% to $139.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $139.1 million, marking a year-over-year decrease of 4167.63%. This contributed to the annual value of $262.3 million for FY2024, which is 2610.19% down from last year.
  • Anaptysbio's Short-term Investments amounted to $139.1 million in Q3 2025, which was down 4167.63% from $221.4 million recorded in Q2 2025.
  • Anaptysbio's Short-term Investments' 5-year high stood at $394.3 million during Q2 2023, with a 5-year trough of $37.7 million in Q3 2021.
  • For the 5-year period, Anaptysbio's Short-term Investments averaged around $256.0 million, with its median value being $279.0 million (2024).
  • In the last 5 years, Anaptysbio's Short-term Investments crashed by 7079.08% in 2021 and then skyrocketed by 91870.63% in 2022.
  • Quarter analysis of 5 years shows Anaptysbio's Short-term Investments stood at $52.4 million in 2021, then soared by 606.41% to $369.9 million in 2022, then dropped by 4.05% to $354.9 million in 2023, then dropped by 26.1% to $262.3 million in 2024, then tumbled by 46.96% to $139.1 million in 2025.
  • Its Short-term Investments was $139.1 million in Q3 2025, compared to $221.4 million in Q2 2025 and $241.3 million in Q1 2025.